Desoxyn Gradumet (methamphetamine) Disease Interactions
There are 13 disease interactions with Desoxyn Gradumet (methamphetamine):
- Cardiovascular
- Glaucoma
- Agitation
- Cardiac Disease
- Glaucoma
- Hypertension
- Liver Disease
- Seizure Disorders
- Substance Abuse
- Psychiatric Disorders
- Renal Dysfunction
- Tics
- Diabetics
Amphetamines (Includes Desoxyn Gradumet) ↔ Cardiovascular
Severe Potential Hazard, High plausibility
Applies to: Cardiovascular Disease, Hyperthyroidism, Cerebral Vascular Disorder, History - Myocardial Infarction, History - Cerebrovascular Disease
The use of amphetamines and amphetamine-like drugs is contraindicated in patients with advanced arteriosclerosis, symptomatic or unstable cardio- or cerebrovascular disease, moderate to severe hypertension, or hyperthyroidism. Like other sympathomimetic amines, amphetamines may cause cardiovascular adverse effects such as palpitation, tachycardia, cardiac arrhythmias, and elevation of blood pressure. Rarely, cardiomyopathy manifested as ventricular hypertrophy and/or congestive heart failure has been reported during chronic amphetamine use. In addition, sudden death has been reported in association with amphetamine therapy at usual dosages in children with structural cardiac abnormalities. In general, amphetamines should not be used in patients with structural cardiac abnormalities. If not otherwise contraindicated, therapy with amphetamines should be administered cautiously in patients with a current or past history of cardiovascular or cerebrovascular disease.
References
- "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
- Ayres PR "Amphetamine cardiomyopathy [letter]." Ann Intern Med 98 (1983): 110
- Gibbs HR "Diet pills and sudden death." N Engl J Med 318 (1988): 1127
- Bashour TT "Acute myocardial infarction resulting from amphetamine abuse: a spasm- thrombus interplay." Am Heart J 128 (1994): 1237-9
- Kokkinos J, Levine SR "Possible association of ischemic stroke with phentermine." Stroke 24 (1993): 310-3
- Smith HJ, Roche AH, Jausch MF, Herdson PB "Cardiomyopathy associated with amphetamine administration." Am Heart J 91 (1976): 792-7
- Ragland AS, Ismail Y, Arsura EL "Myocardial infarction after amphetamine use." Am Heart J 125 (1993): 247-9
- "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
- "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
- Douglas A, Douglas JG, Robertson CE, Munro JF "Plasma phentermine levels, weight loss and side-effects." Int J Obes 7 (1983): 591-5
- "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
- "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
Amphetamines (Includes Desoxyn Gradumet) ↔ Glaucoma
Severe Potential Hazard, Moderate plausibility
Applies to: Glaucoma/Intraocular Hypertension
The use of amphetamines and amphetamine-like drugs is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. Like other sympathomimetic amines, amphetamines can induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, these agents should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.
References
- "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
- "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
- "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
- "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
- "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Agitation
Severe Potential Hazard, High plausibility
Applies to: Psychosis, Anxiety/Stress, Neurosis
The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.
References
- "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
- "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
- "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
- "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
- "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
- "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Cardiac Disease
Severe Potential Hazard, Moderate plausibility
Applies to: Heart Disease, Hypertension, Pheochromocytoma, Hyperthyroidism, Peripheral Arterial Disease
The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc. Sudden death has been reported in adults and children taking CNS stimulant treatment. Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment. A careful assessment of the cardiovascular status should be done in patients being considered for treatment. This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram). Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.
References
- "Product Information. Dopram (doxapram)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Glaucoma
Severe Potential Hazard, Moderate plausibility
Applies to: Glaucoma/Intraocular Hypertension
The use of most CNS stimulants is contraindicated in patients with glaucoma, as these agents exhibit sympathomimetic activity and may induce mydriasis provoking an increase in intraocular pressure.
References
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Hypertension
Severe Potential Hazard, Moderate plausibility
Applies to: Hypertension
CNS stimulant medications have shown to increase blood pressure and their use is contraindicated in patients with severe hypertension. Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions. All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.
References
- "Product Information. Dopram (doxapram)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Liver Disease
Severe Potential Hazard, Moderate plausibility
Applies to: Liver Disease
In general, CNS stimulants are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly. Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury. Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Seizure Disorders
Severe Potential Hazard, Moderate plausibility
Applies to: Seizures
Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures. These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures. Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures. If seizures appear, therapy should be discontinued.
References
- American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Substance Abuse
Severe Potential Hazard, High plausibility
Applies to: Alcoholism, Drug Abuse/Dependence
Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse. Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use. Frank psychotic episodes may also occur in association with chronic intoxication. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of amphetamines is considered by manufacturers to be contraindicated in such patients.
References
- "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
- "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
- "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
- "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Psychiatric Disorders
Moderate Potential Hazard, Moderate plausibility
Applies to: Psychosis, Depression
The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder. Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes. Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder. All patients receiving treatment should be screened for bipolar disease prior to initiation. If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered. CNS stimulants are contraindicated in patients with marked agitation or anxiety.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Renal Dysfunction
Moderate Potential Hazard, Moderate plausibility
Applies to: Renal Dysfunction
Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response. The dosage should be adjusted accordingly.
References
- "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Cns Stimulants (Includes Desoxyn Gradumet) ↔ Tics
Moderate Potential Hazard, High plausibility
Applies to: Tic Disorder
Central nervous system (CNS) stimulants have been reported to exacerbate Tourette's syndrome and other motor and phonic tics. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.
References
- "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Cylert (pemoline)." Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
- "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
- "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.
- "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
- "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.
Obesity Drugs (Includes Desoxyn Gradumet) ↔ Diabetics
Moderate Potential Hazard, High plausibility
Applies to: Diabetes Type 2
Obese, type 2 diabetic patients who achieve weight loss may demonstrate improved metabolic control of their disease as a result of their reduced weight. Therefore, patients with type 2 diabetes mellitus should be monitored during weight-reduction therapy (or therapy that may be expected to induce significant weight loss as a secondary effect) for hypoglycemia and reduced need for oral hypoglycemic medication or insulin, and the dosages of these agents adjusted accordingly. Patients should be apprised of the risk of hypoglycemia and be alert to potential signs and symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation.
References
- "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.
- "Product Information. Xenical (orlistat)." Roche Laboratories, Nutley, NJ.
- "Product Information. Dexedrine (dextroamphetamine)" SmithKline Beecham, Philadelphia, PA.
- "Product Information. Prelu-2 (phendimetrazine)" Boehringer-Ingelheim, Ridgefield, CT.
- "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Desoxyn (methamphetamine)" Abbott Pharmaceutical, Abbott Park, IL.
- "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.
- "Product Information. Fastin (phentermine)." SmithKline Beecham, Philadelphia, PA.
- "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.
Desoxyn Gradumet (methamphetamine) drug Interactions
There are 616 drug interactions with Desoxyn Gradumet (methamphetamine)
Desoxyn Gradumet (methamphetamine) alcohol/food Interactions
There are 3 alcohol/food interactions with Desoxyn Gradumet (methamphetamine)
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No information available. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.